Condition: Multiple System Atrophy - Parkinsonian Subtype (MSA-P) · Multiple System Atrophy, MSA · Sponsor: Beijing Tiantan Hospital
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of Aleeto in the treatment of patients with multiple system atrophy (MSA).
This description comes directly from the study's public registry record.
Weiqi Chen, M.D. · 8615652813380 · weiqichen@aliyun.com
Lei Guo · 8619801237597 · guolei53@aliyun.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06765733